Investment Thesis
AbCellera is a pre-commercial biotech company burning significant cash with negative margins across all profitability measures, though revenue growth of 160.6% YoY demonstrates early commercial traction. The company has adequate liquidity (11.3x current ratio, $128.5M cash) to fund operations, but the path to profitability remains unclear with operating losses of $217.1M and free cash flow of -$174.1M on just $75.1M in revenue.
ABCL Strengths
- Exceptional revenue growth of 160.6% YoY demonstrates market demand and successful commercialization of antibody discovery platform
- Strong balance sheet with $966.9M stockholders equity and negligible debt (0.00x debt/equity ratio)
- Excellent liquidity position with 11.32x current ratio providing 12+ months of cash runway at current burn rates
ABCL Risks
- Severe cash burn with -$174.1M free cash flow and -$131.3M operating cash flow unsustainable without additional capital or significant revenue acceleration
- Profitability metrics deeply negative (operating margin -289%, net margin -194.9%) with no clear path to breakeven visible in current trajectory
- Business model economics uncertain with negative gross margins implied, suggesting current revenue does not cover direct costs of delivery
- Operating losses of $217.1M represent 2.9x annual revenue, indicating massive scaling required before profitability achievable
Key Metrics to Watch
- Quarterly revenue growth rates and customer concentration to validate sustainability of 160% growth
- Gross margin expansion as volume scales and manufacturing efficiency improves
- Monthly cash burn rate and projected runway to breakeven or next capital requirement
- Operating expense reduction through operational leverage as revenue scales
ABCL Financial Metrics
Revenue
$75.1M
Net Income
$-146.4M
EPS (Diluted)
$-0.49
Free Cash Flow
$-174.1M
Total Assets
$1.4B
Cash Position
$128.5M
ABCL Profitability Ratios
Gross Margin
N/A
Operating Margin
-289.0%
Net Margin
-194.9%
ROE
-15.1%
ROA
-10.8%
FCF Margin
-231.7%
ABCL Balance Sheet & Liquidity
Current Ratio
11.32x
Quick Ratio
11.23x
Debt/Equity
0.00x
Debt/Assets
28.7%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: Mar 18, 2026 |
Data as of: 2025-12-31 |
Powered by Claude AI